Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomepromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.82 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.46 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.82 |
| ▸ | HTR1A | P08908 | 4/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.82 |
| ▸ | DRD1 | P21728 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.82 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.82 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomepromazine SCHEMBL29727144 | 1.00 | LMNA (0.82) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL218717 | 1.00 | LMNA (0.82) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL27701483 | 0.93 | LMNA (0.88) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29508092 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL8762418 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL23859840 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL6944555 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29425180 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL25462 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29384983 | 0.91 | CYP2D6 (1.00) | LMNACHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410474-B2 | Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient | NORTHWESTERN UNIVERSITY (US) | 2025-09-09 | — | — | US | disclosed |
| WO-2025033273-A1 | DISPENSATION CONTROL DEVICE, MEDICINE DISPENSATION SYSTEM, AND MEDICINE DISPENSATION PROGRAM | 株式会社湯山製作所 | 2025-02-13 | — | — | WO | disclosed |
| US-20240285549-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CONSTANCE THERAPEUTICS, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240033312-A1 | CANNABIS OIL EXTRACTS AND COMPOSITIONS | CONSTANCE THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | US | disclosed |
| US-20230386637-A1 | Polymorphisms for Predicting Treatment Response to Antipsychotic Drugs and Identifying New Drug Targets | NORTHWESTERN UNIVERSITY | 2023-11-30 | — | — | US | disclosed |
| US-11596618-B2 | Oral cannabinoid delivery formulations with mouthfeel experience enhancers | Resurgent Biosciences, Inc. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220331344-A1 | ORAL FORMULATIONS OF PSYCHOTROPIC MACROFUNGUS BOTANICAL EXTRACTS WITH MOUTHFEEL EXPERIENCE ENHANCERS | CHICAGO ATLANTIC ADMIN, LLC | 2022-10-20 | — | — | US | disclosed |
| US-20220177970-A1 | METHODS, KITS, AND DEVICES FOR DIAGNOSING, PROGNOSING, AND TREATING PSYCHIATRIC DISORDERS IN A PATIENT | NORTHWESTERN UNIVERSITY | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240033312-A1 | CANNABIS OIL EXTRACTS AND COMPOSITIONS | CNR2, CNR1, DNER | DRD3 332/4885DRD2 213/4885DRD4 229/4885 |
| US-20240285549-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CNR1, CNR2, PROC | DRD3 311/4885DRD2 215/4885DRD4 248/4885 |
| US-20220331344-A1 | ORAL FORMULATIONS OF PSYCHOTROPIC MACROFUNGUS BOTANICAL EXTRACTS WITH MOUTHFEEL EXPERIENCE ENHANCERS | MB, MLEC, NISCH | DRD3 583/4885DRD2 145/4885DRD4 521/4885 |
| US-11596618-B2 | Oral cannabinoid delivery formulations with mouthfeel experience enhancers | CNR2, CNR1, CPNE4 | DRD3 400/4885DRD2 224/4885DRD4 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.